Patients with relapsed or refractory multiple myeloma who achieved sustained minimal residual disease negativity in the DREAMM-7 trial
Year: 2026
Type: conference-abstract
DOI: 10.67209/hgcg2985
Authors: Mar.a-Victoria Mateos, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P. Joy Ho, Roman H.jek, Kihyun Kim, Sebastian Grosicki, Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Gracia Aparecida-Martinez, Anna Sureda Balar, Jie Ma, Yinjiao Ma, Maureen Nichols, Jorge Mouro, Zeyad Khalaf, Hena Baig, Benga Kazeem, Nick Pirooz, Sybil Varghese, Joe Lee, Lydia Eccersley, Vania Hungria
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7202353097